TendoNova

Executive Summary

TendoNova is a privately held medical device company based in Atlanta, Georgia, founded in 2015 with a focus on developing innovative treatments for tendonitis. The company addresses common conditions such as plantar fasciitis, tennis elbow, golfer's elbow, Achilles tendonitis, peroneal tendonitis, runner's knee, and patellar pain. By targeting a large and underserved patient population suffering from chronic tendon inflammation, TendoNova aims to provide a non-invasive or minimally invasive alternative to traditional therapies like physical therapy, corticosteroid injections, or surgery. The global tendonitis treatment market is substantial and growing, driven by an active aging population and increasing sports-related injuries. While the company has not publicly disclosed funding, valuation, or revenue, its presence in the competitive medical device space suggests a need for regulatory clearances (e.g., FDA 510(k)) and clinical validation to gain traction. With a focused product portfolio and a clear value proposition, TendoNova is positioned to capture market share if it can demonstrate superior efficacy and safety compared to existing options.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Clearance for Lead Device60% success
• Q2 2027Publication of Clinical Trial Results50% success
• Q1 2027Strategic Partnership or Distribution Agreement40% success